NASDAQ:LQDA Liquidia (LQDA) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free LQDA Stock Alerts $12.55 -0.40 (-3.09%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$12.40▼$13.0750-Day Range$12.55▼$16.7352-Week Range$5.71▼$16.99Volume1.09 million shsAverage Volume868,271 shsMarket Capitalization$954.18 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Liquidia alerts: Email Address Liquidia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside67.3% Upside$21.00 Price TargetShort InterestBearish9.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 6 Articles This WeekInsider TradingSelling Shares$1.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.01) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector530th out of 907 stocksPharmaceutical Preparations Industry244th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingLiquidia has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLiquidia has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.77% of the outstanding shares of Liquidia have been sold short.Short Interest Ratio / Days to CoverLiquidia has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Liquidia has recently increased by 2.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLiquidia does not currently pay a dividend.Dividend GrowthLiquidia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LQDA. Previous Next 2.7 News and Social Media Coverage News SentimentLiquidia has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Liquidia this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for LQDA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Liquidia to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Liquidia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,100,444.00 in company stock.Percentage Held by Insiders31.60% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Liquidia are expected to grow in the coming year, from ($1.01) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Liquidia is -10.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Liquidia is -10.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLiquidia has a P/B Ratio of 17.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Liquidia Stock (NASDAQ:LQDA)Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Read More LQDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LQDA Stock News HeadlinesApril 24, 2024 | insidertrades.comLiquidia Co. (NASDAQ:LQDA) Insider Rajeev Saggar Sells 1,649 SharesApril 19, 2024 | insidertrades.comRussell Schundler Sells 2,060 Shares of Liquidia Co. (NASDAQ:LQDA) StockApril 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 16, 2024 | insidertrades.comJason Adair Sells 1,189 Shares of Liquidia Co. (NASDAQ:LQDA) StockApril 19, 2024 | americanbankingnews.comRoger Jeffs Sells 8,360 Shares of Liquidia Co. (NASDAQ:LQDA) StockApril 19, 2024 | americanbankingnews.comMichael Kaseta Sells 3,136 Shares of Liquidia Co. (NASDAQ:LQDA) StockApril 18, 2024 | investing.comLiquidia Corp CEO sells $121,888 in company stockApril 18, 2024 | investing.comLiquidia Corp executive sells shares worth over $23,000April 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 16, 2024 | americanbankingnews.comLiquidia Co. (NASDAQ:LQDA) Insider Jason Adair Sells 1,189 Shares of StockApril 3, 2024 | finance.yahoo.comLiquidia Corporation (NASDAQ:LQDA) has caught the attention of institutional investors who hold a sizeable 38% stakeApril 2, 2024 | globenewswire.comLiquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | markets.businessinsider.comBuy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies’ YutrepiaApril 1, 2024 | marketwatch.comLiquidia's Yutrepia Cleared for Potential FDA Approval Following Court RulingApril 1, 2024 | globenewswire.comUpdate on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powderMarch 29, 2024 | bizjournals.comMorrisville firm wins in federal court, targets FDA approvalMarch 28, 2024 | msn.comLiquidia gains after court win in patent dispute with United TherapeuticsMarch 21, 2024 | investing.comLiquidia Corp CEO sells over $450k in company stockMarch 21, 2024 | investing.comLiquidia Corp CMO sells over $119k in company stockMarch 20, 2024 | finance.yahoo.comInsider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA)March 20, 2024 | finance.yahoo.comChief Medical Officer Rajeev Saggar Sells Shares of Liquidia Corp (LQDA)March 16, 2024 | finance.yahoo.comLQDA Apr 2024 7.500 callMarch 15, 2024 | seekingalpha.comLiquidia Corporation (LQDA) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Liquidia Technologies with Doubling Price Target on Yutrepia’s Promising ProspectsMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Legend Biotech (LEGN)March 14, 2024 | finance.yahoo.comLiquidia Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Liquidia Technologies Amid Favorable Legal Rulings and Yutrepia’s Market PotentialSee More Headlines Receive LQDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liquidia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/24/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LQDA CUSIPN/A CIK1819576 Webwww.liquidia.com Phone(919) 328-4400FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$32.00 Low Stock Price Target$3.00 Potential Upside/Downside+67.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,500,000.00 Net Margins-448.89% Pretax Margin-448.89% Return on Equity-132.16% Return on Assets-65.35% Debt Debt-to-Equity RatioN/A Current Ratio4.85 Quick Ratio4.85 Sales & Book Value Annual Sales$17.49 million Price / Sales54.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book17.19Miscellaneous Outstanding Shares76,030,000Free Float52,003,000Market Cap$954.18 million OptionableOptionable Beta0.16 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Roger A. Jeffs Ph.D. (Age 62)CEO & Director Comp: $532.23kMr. Michael Kaseta (Age 47)COO & CFO Comp: $627.85kMr. Russell Schundler (Age 49)General Counsel & Corporate Secretary Comp: $541.92kMr. William R. Kenan Jr.Co-FounderDr. Ginger DenisonCo-FounderJennifer AlmondDirector of Investor Relations & Corporate CommunicationsMs. Sarah Krepp SPHRVice President of People & CultureMr. Jason Adair (Age 50)Chief Business Officer Dr. Tushar Shah M.D. (Age 63)Senior Vice President of Product Development Comp: $792.36kMr. Scott Moomaw (Age 53)Chief Commercial Officer More ExecutivesKey CompetitorsABIVAX Société AnonymeNASDAQ:ABVXMacroGenicsNASDAQ:MGNXInnovivaNASDAQ:INVACentessa PharmaceuticalsNASDAQ:CNTAZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsSimplicity Wealth LLCBought 33,250 shares on 4/24/2024Ownership: 0.044%McAdam LLCSold 753 shares on 4/23/2024Ownership: 0.018%Rajeev SaggarSold 1,649 sharesTotal: $22,558.32 ($13.68/share)Roger JeffsSold 8,360 sharesTotal: $121,888.80 ($14.58/share)Russell SchundlerSold 2,060 sharesTotal: $30,034.80 ($14.58/share)View All Insider TransactionsView All Institutional Transactions LQDA Stock Analysis - Frequently Asked Questions Should I buy or sell Liquidia stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LQDA shares. View LQDA analyst ratings or view top-rated stocks. What is Liquidia's stock price target for 2024? 5 analysts have issued 12 month price objectives for Liquidia's shares. Their LQDA share price targets range from $3.00 to $32.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts. How have LQDA shares performed in 2024? Liquidia's stock was trading at $12.03 on January 1st, 2024. Since then, LQDA shares have increased by 4.3% and is now trading at $12.55. View the best growth stocks for 2024 here. When is Liquidia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LQDA earnings forecast. How were Liquidia's earnings last quarter? Liquidia Co. (NASDAQ:LQDA) announced its earnings results on Wednesday, March, 13th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.19. The firm earned $4.53 million during the quarter, compared to analyst estimates of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative trailing twelve-month return on equity of 132.16%. What ETFs hold Liquidia's stock? ETFs with the largest weight of Liquidia (NASDAQ:LQDA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Liquidia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA). When did Liquidia IPO? Liquidia (LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are Liquidia's major shareholders? Liquidia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Simplicity Wealth LLC (0.04%) and McAdam LLC (0.02%). Insiders that own company stock include Arthur S Kirsch, Caligan Partners Lp, Jason Adair, Michael Kaseta, Rajeev Saggar, Robert A Lippe, Roger Jeffs, Russell Schundler and Scott Moomaw. View institutional ownership trends. How do I buy shares of Liquidia? Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LQDA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liquidia Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
